FDA Reviews Unapproved Peptide Substances Amid Rising Popularity

The Food and Drug Administration (FDA) is examining seven unapproved peptide substances noted for their health benefits. Scheduled for review on July 23 and 24 at the FDA’s White Oak Campus in Silver Spring, Maryland, the focus is whether these peptides should join the 503A Bulks List, allowing use in specific compounded prescription drugs.

These substances, though not FDA-approved, are accessible through wellness clinics, compounding operations, and some online sellers. Consumer demand for peptides remains high, attributed to their use in weight loss, muscle building, performance enhancement, chronic disease management, and wound repair.

Peptides Under Review

According to FDA documents, the peptides under review include:

• BPC-157 – Proposed for ulcerative colitis, available in oral capsules, nasal spray, injections, transdermal cream, and rectal suppository forms.
• TB-500 – Intended for wound healing, proposed as subcutaneous or intramuscular injections.
• KPV – Aimed at wound healing and inflammatory conditions, in cream and gel forms.
• MOTS-c – For obesity and osteoporosis, suggested as subcutaneous injections.
• Semax – For cerebral ischemia, migraine, and trigeminal neuralgia, in intranasal spray and subcutaneous injections.
• Emideltide – Targeting opioid withdrawal, chronic insomnia, and narcolepsy, as subcutaneous injections.
• Epitalon – For insomnia, available as subcutaneous injections.

“These medications aim to help people live healthier lives,” said Dr. Alex Tatem, a board-certified urologist.

Performance and Safety

Dr. Alex Tatem, a peptide expert and member of Rugiet’s Medical Advisory Board, will present testimony at the FDA hearings. Tatem highlighted the safety of substances like BPC-157 and TB-500, shown to facilitate healing without significant adverse effects, unlike some over-the-counter options such as ibuprofen.

The FDA remains cautious, indicating insufficient clinical evidence on these peptides’ safety and efficacy. Dr. Marc Siegel, Fox News’ senior medical analyst, expressed the need for comprehensive studies before considering approval.

Next Steps

Tatem anticipates a challenging review outcome, yet hopes FDA committee members acknowledge existing real-world data from millions of doses administered between 2014 and 2023. If recommended, the FDA must finalize its review process for formal inclusion on the 503A Bulks List.

The FDA holds the discretion to accept or ignore the committee recommendations. Peptide enthusiasts are encouraged to contact local representatives to advocate for safe, regulated peptide access.

Fox News Digital sought comments from the FDA and ibuprofen product manufacturer Haleon.